Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison

Suzanne V. Arnold, Jonathan Yap, Carolyn S.P. Lam, Fengming Tang, Wan T. Tay, Tiew H.K. Teng, Darren K McGuire, James L. Januzzi, Gregg C. Fonarow, Frederick A. Masoudi, Mikhail Kosiborod

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims: To compare the management of patients with diabetes and heart failure with reduced ejection fraction (HFrEF) in the United States and Asia to understand variations in treatment patterns across different healthcare systems. Materials and methods: Our cohort included patients with diabetes and HFrEF (ejection fraction <40%) from a US-based registry of adults with diabetes (2013-2016, electronic health records) and a multi-national Asian registry of adults with heart failure (2010-2016, prospective registry). Asian countries were categorized as high income (HI) or low income (LI), according to the United Nations classification. Rates of use of guideline-directed medical therapies (determined through review of active medication lists) were compared across regions. Results: Patients with diabetes and HFrEF in the United States (n = 28 877) were older, had higher body mass indices, and were more likely to have coronary disease than those in Asia (n = 2235). Compared with US patients, the use of guideline-directed medical therapy for HFrEF was lower in patients in LI Asian countries (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers: patients in the United States, 77% vs. patients in HI Asian countries, 76% vs patients in LI Asian countries, 69%; β-blockers: patients in the United States, 91% vs. patients in HI Asian countries, 87% vs. patients in LI Asian countries, 69%; P < 0.001 for both). Insulin was used more commonly in the United States (44% vs. 24% vs. 25%, respectively; P < 0.001), whereas sulphonylureas were more often prescribed in Asian countries (42% vs. 52% vs. 54%; respectively, P < 0.001). Thiazolidinediones were prescribed in 6% of US patients compared with <1% of patients in Asia. The use of newer diabetes medications was <5% in all. Conclusion: In both the United States and Asia, opportunities for improvement in the use of evidence-based therapies exist for patients with both diabetes and HFrEF. Effective tools to guide medication choices for these complex, high-risk patients could have substantial impact on quality and outcomes.

Original languageEnglish (US)
JournalDiabetes, Obesity and Metabolism
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Heart Failure
Registries
Guidelines
Thiazolidinediones
United Nations
Electronic Health Records
Angiotensin Receptor Antagonists
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Coronary Disease
Body Mass Index
Insulin
Delivery of Health Care

Keywords

  • diabetes mellitus
  • heart failure
  • quality of care
  • registries
  • systolic dysfunction

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Arnold, S. V., Yap, J., Lam, C. S. P., Tang, F., Tay, W. T., Teng, T. H. K., ... Kosiborod, M. (Accepted/In press). Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13511

Management of patients with diabetes and heart failure with reduced ejection fraction : An international comparison. / Arnold, Suzanne V.; Yap, Jonathan; Lam, Carolyn S.P.; Tang, Fengming; Tay, Wan T.; Teng, Tiew H.K.; McGuire, Darren K; Januzzi, James L.; Fonarow, Gregg C.; Masoudi, Frederick A.; Kosiborod, Mikhail.

In: Diabetes, Obesity and Metabolism, 01.01.2018.

Research output: Contribution to journalArticle

Arnold, Suzanne V. ; Yap, Jonathan ; Lam, Carolyn S.P. ; Tang, Fengming ; Tay, Wan T. ; Teng, Tiew H.K. ; McGuire, Darren K ; Januzzi, James L. ; Fonarow, Gregg C. ; Masoudi, Frederick A. ; Kosiborod, Mikhail. / Management of patients with diabetes and heart failure with reduced ejection fraction : An international comparison. In: Diabetes, Obesity and Metabolism. 2018.
@article{f0addbae29c94c2b86c13449b0039f4f,
title = "Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison",
abstract = "Aims: To compare the management of patients with diabetes and heart failure with reduced ejection fraction (HFrEF) in the United States and Asia to understand variations in treatment patterns across different healthcare systems. Materials and methods: Our cohort included patients with diabetes and HFrEF (ejection fraction <40{\%}) from a US-based registry of adults with diabetes (2013-2016, electronic health records) and a multi-national Asian registry of adults with heart failure (2010-2016, prospective registry). Asian countries were categorized as high income (HI) or low income (LI), according to the United Nations classification. Rates of use of guideline-directed medical therapies (determined through review of active medication lists) were compared across regions. Results: Patients with diabetes and HFrEF in the United States (n = 28 877) were older, had higher body mass indices, and were more likely to have coronary disease than those in Asia (n = 2235). Compared with US patients, the use of guideline-directed medical therapy for HFrEF was lower in patients in LI Asian countries (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers: patients in the United States, 77{\%} vs. patients in HI Asian countries, 76{\%} vs patients in LI Asian countries, 69{\%}; β-blockers: patients in the United States, 91{\%} vs. patients in HI Asian countries, 87{\%} vs. patients in LI Asian countries, 69{\%}; P < 0.001 for both). Insulin was used more commonly in the United States (44{\%} vs. 24{\%} vs. 25{\%}, respectively; P < 0.001), whereas sulphonylureas were more often prescribed in Asian countries (42{\%} vs. 52{\%} vs. 54{\%}; respectively, P < 0.001). Thiazolidinediones were prescribed in 6{\%} of US patients compared with <1{\%} of patients in Asia. The use of newer diabetes medications was <5{\%} in all. Conclusion: In both the United States and Asia, opportunities for improvement in the use of evidence-based therapies exist for patients with both diabetes and HFrEF. Effective tools to guide medication choices for these complex, high-risk patients could have substantial impact on quality and outcomes.",
keywords = "diabetes mellitus, heart failure, quality of care, registries, systolic dysfunction",
author = "Arnold, {Suzanne V.} and Jonathan Yap and Lam, {Carolyn S.P.} and Fengming Tang and Tay, {Wan T.} and Teng, {Tiew H.K.} and McGuire, {Darren K} and Januzzi, {James L.} and Fonarow, {Gregg C.} and Masoudi, {Frederick A.} and Mikhail Kosiborod",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/dom.13511",
language = "English (US)",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Management of patients with diabetes and heart failure with reduced ejection fraction

T2 - An international comparison

AU - Arnold, Suzanne V.

AU - Yap, Jonathan

AU - Lam, Carolyn S.P.

AU - Tang, Fengming

AU - Tay, Wan T.

AU - Teng, Tiew H.K.

AU - McGuire, Darren K

AU - Januzzi, James L.

AU - Fonarow, Gregg C.

AU - Masoudi, Frederick A.

AU - Kosiborod, Mikhail

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: To compare the management of patients with diabetes and heart failure with reduced ejection fraction (HFrEF) in the United States and Asia to understand variations in treatment patterns across different healthcare systems. Materials and methods: Our cohort included patients with diabetes and HFrEF (ejection fraction <40%) from a US-based registry of adults with diabetes (2013-2016, electronic health records) and a multi-national Asian registry of adults with heart failure (2010-2016, prospective registry). Asian countries were categorized as high income (HI) or low income (LI), according to the United Nations classification. Rates of use of guideline-directed medical therapies (determined through review of active medication lists) were compared across regions. Results: Patients with diabetes and HFrEF in the United States (n = 28 877) were older, had higher body mass indices, and were more likely to have coronary disease than those in Asia (n = 2235). Compared with US patients, the use of guideline-directed medical therapy for HFrEF was lower in patients in LI Asian countries (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers: patients in the United States, 77% vs. patients in HI Asian countries, 76% vs patients in LI Asian countries, 69%; β-blockers: patients in the United States, 91% vs. patients in HI Asian countries, 87% vs. patients in LI Asian countries, 69%; P < 0.001 for both). Insulin was used more commonly in the United States (44% vs. 24% vs. 25%, respectively; P < 0.001), whereas sulphonylureas were more often prescribed in Asian countries (42% vs. 52% vs. 54%; respectively, P < 0.001). Thiazolidinediones were prescribed in 6% of US patients compared with <1% of patients in Asia. The use of newer diabetes medications was <5% in all. Conclusion: In both the United States and Asia, opportunities for improvement in the use of evidence-based therapies exist for patients with both diabetes and HFrEF. Effective tools to guide medication choices for these complex, high-risk patients could have substantial impact on quality and outcomes.

AB - Aims: To compare the management of patients with diabetes and heart failure with reduced ejection fraction (HFrEF) in the United States and Asia to understand variations in treatment patterns across different healthcare systems. Materials and methods: Our cohort included patients with diabetes and HFrEF (ejection fraction <40%) from a US-based registry of adults with diabetes (2013-2016, electronic health records) and a multi-national Asian registry of adults with heart failure (2010-2016, prospective registry). Asian countries were categorized as high income (HI) or low income (LI), according to the United Nations classification. Rates of use of guideline-directed medical therapies (determined through review of active medication lists) were compared across regions. Results: Patients with diabetes and HFrEF in the United States (n = 28 877) were older, had higher body mass indices, and were more likely to have coronary disease than those in Asia (n = 2235). Compared with US patients, the use of guideline-directed medical therapy for HFrEF was lower in patients in LI Asian countries (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers: patients in the United States, 77% vs. patients in HI Asian countries, 76% vs patients in LI Asian countries, 69%; β-blockers: patients in the United States, 91% vs. patients in HI Asian countries, 87% vs. patients in LI Asian countries, 69%; P < 0.001 for both). Insulin was used more commonly in the United States (44% vs. 24% vs. 25%, respectively; P < 0.001), whereas sulphonylureas were more often prescribed in Asian countries (42% vs. 52% vs. 54%; respectively, P < 0.001). Thiazolidinediones were prescribed in 6% of US patients compared with <1% of patients in Asia. The use of newer diabetes medications was <5% in all. Conclusion: In both the United States and Asia, opportunities for improvement in the use of evidence-based therapies exist for patients with both diabetes and HFrEF. Effective tools to guide medication choices for these complex, high-risk patients could have substantial impact on quality and outcomes.

KW - diabetes mellitus

KW - heart failure

KW - quality of care

KW - registries

KW - systolic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85054408953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054408953&partnerID=8YFLogxK

U2 - 10.1111/dom.13511

DO - 10.1111/dom.13511

M3 - Article

C2 - 30136348

AN - SCOPUS:85054408953

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

ER -